Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'

Grössmann N;Wolf S;Rothschedl E;Wild C;;
esmo open 2021 Vol. 6 pp. -
149
n2021esmotwelve

Abstract

Applying both versions of the ESMO-MCBS can help to identify potentially beneficial cancer indications, but also those with rather uncertain or low clinical benefit and thus, support the fair allocation of limited health care resources.

Keywords

National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine drug approval pmid:34087744 pmc8182388 doi:10.1016/j.esmoop.2021.100166 n grössmann s wolf c wild antineoplastic agents* / therapeutic use medical oncology neoplasms* / drug therapy

Access

URL:
http://www.ncbi.nlm.nih.gov/pubmed/34087744

Citation

ID: 273575
Ref Key: n2021esmotwelve
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
273575
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store